AR092955A1 - Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona - Google Patents
Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanonaInfo
- Publication number
- AR092955A1 AR092955A1 ARP130103661A ARP130103661A AR092955A1 AR 092955 A1 AR092955 A1 AR 092955A1 AR P130103661 A ARP130103661 A AR P130103661A AR P130103661 A ARP130103661 A AR P130103661A AR 092955 A1 AR092955 A1 AR 092955A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- group
- twice
- membered
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- SDCMHPPKMQZPPJ-UHFFFAOYSA-N 3-phenyl-4h-quinazoline Chemical compound C1=NC2=CC=CC=C2CN1C1=CC=CC=C1 SDCMHPPKMQZPPJ-UHFFFAOYSA-N 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- -1 2,3-dihydro-benzo [1,4] dioxinyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 3
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- SFEORRVCCVBBKD-NRFANRHFSA-N (2-phenylphenyl)-[(2S)-2-(3-pyridin-3-yl-1H-1,2,4-triazol-5-yl)pyrrolidin-1-yl]methanone Chemical compound C1(=C(C=CC=C1)C(=O)N1[C@@H](CCC1)C1=NC(=NN1)C=1C=NC=CC1)C1=CC=CC=C1 SFEORRVCCVBBKD-NRFANRHFSA-N 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 108050000742 Orexin Receptor Proteins 0.000 abstract 1
- 102000008834 Orexin receptor Human genes 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188019 | 2012-10-10 | ||
| EP13157809 | 2013-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092955A1 true AR092955A1 (es) | 2015-05-06 |
Family
ID=49765598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103661A AR092955A1 (es) | 2012-10-10 | 2013-10-09 | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9493446B2 (enExample) |
| EP (1) | EP2906553B1 (enExample) |
| JP (1) | JP6244365B2 (enExample) |
| KR (1) | KR102151288B1 (enExample) |
| CN (1) | CN104703980B (enExample) |
| AR (1) | AR092955A1 (enExample) |
| AU (1) | AU2013328301A1 (enExample) |
| BR (1) | BR112015007516A2 (enExample) |
| CA (1) | CA2885180C (enExample) |
| EA (1) | EA201500399A1 (enExample) |
| IL (1) | IL238052A0 (enExample) |
| MX (1) | MX2015004638A (enExample) |
| PH (1) | PH12015500627A1 (enExample) |
| SG (1) | SG11201502493XA (enExample) |
| TW (1) | TW201414727A (enExample) |
| WO (1) | WO2014057435A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101995683B1 (ko) | 2012-06-04 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체 |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
| UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| US9914720B2 (en) | 2013-12-03 | 2018-03-13 | Idorsia Pharmaceuticals Ltd | Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| HK1225734B (en) | 2013-12-04 | 2017-09-15 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| US9938276B2 (en) | 2014-12-19 | 2018-04-10 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
| CN106986859B (zh) * | 2016-01-20 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚衍生物及其用途 |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| KR102582197B1 (ko) | 2017-05-03 | 2023-09-22 | 이도르시아 파마슈티컬스 리미티드 | 2-([1,2,3]트리아졸-2-일)-벤조산 유도체의 제조 |
| WO2019018795A1 (en) * | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| WO2019084463A1 (en) * | 2017-10-26 | 2019-05-02 | Southern Research Institute | OXADIAZOLES AND THIADIAZOLES AS INHIBITORS OF TGF-BETA |
| EA202092225A1 (ru) | 2018-03-23 | 2021-02-09 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN112566636A (zh) | 2018-04-25 | 2021-03-26 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| DK3917616T3 (da) | 2019-01-31 | 2025-07-21 | Takeda Pharmaceuticals Co | Heterocykliske forbindelser og anvendelse deraf |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN116783182B (zh) * | 2021-02-02 | 2025-08-29 | 南京明德新药研发有限公司 | 四氢吡咯并环化合物及其应用 |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
| US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
| US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| CN119613393A (zh) * | 2024-11-13 | 2025-03-14 | 深圳华津生物科技有限公司 | Trpc5抑制剂及其制备方法和应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| JP4611608B2 (ja) | 2000-06-16 | 2011-01-12 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとして使用するためのピペリジン |
| ES2234929T3 (es) | 2000-11-28 | 2005-07-01 | Smithkline Beecham Plc | Derivados de morfolina como antagonistas de los receptores de orexina. |
| JP2004534026A (ja) | 2001-05-05 | 2004-11-11 | スミスクライン ビーチャム パブリック リミテッド カンパニー | オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体 |
| CN100448874C (zh) | 2001-05-05 | 2009-01-07 | 史密斯克莱·比奇曼公司 | N-芳酰基环胺 |
| CA2451464A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| DE10240818A1 (de) * | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| JP2006504695A (ja) | 2002-09-18 | 2006-02-09 | グラクソ グループ リミテッド | オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| PE20050226A1 (es) | 2003-06-04 | 2005-05-18 | Aventis Pharma Sa | Productos aril-heteroaromaticos y composiciones que los contienen |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CA2557163C (en) | 2004-03-01 | 2011-08-16 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US7269781B2 (en) | 2004-06-25 | 2007-09-11 | Hewlett-Packard Development Company, L.P. | Discrete universal denoising with reliability information |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
| KR101065239B1 (ko) | 2006-03-15 | 2011-09-16 | 액테리온 파마슈티칼 리미티드 | 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체 |
| JP2009543785A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| CA2659155A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
| CA2659299A1 (en) | 2006-08-15 | 2008-02-21 | Actelion Pharmaceuticals Ltd | Azetidine compounds |
| DE602007009284D1 (de) | 2006-09-29 | 2010-10-28 | Actelion Pharmaceuticals Ltd | 3-aza-bicycloä3.1.0ühexanderivate |
| ATE496043T1 (de) | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| ATE483707T1 (de) | 2007-05-14 | 2010-10-15 | Actelion Pharmaceuticals Ltd | 2-cyclopropylthiazolderivate |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5268120B2 (ja) | 2007-05-22 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンゾイミダゾロンキマーゼ阻害薬 |
| AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| ATE518857T1 (de) | 2007-06-01 | 2011-08-15 | Hoffmann La Roche | Piperidin-amidderivate |
| ATE524466T1 (de) | 2007-07-03 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-azabicycloä3.3.0üoktanverbindungen |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| EP2176258A1 (en) | 2007-07-03 | 2010-04-21 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| US7751938B2 (en) | 2007-07-05 | 2010-07-06 | Panasonic Corporation | Robot arm control device and control method, robot, and control program |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| TW200904799A (en) | 2007-07-27 | 2009-02-01 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2009016564A2 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| CN101874030B (zh) | 2007-09-24 | 2012-11-14 | 埃科特莱茵药品有限公司 | 用作食欲素受体拮抗剂的吡咯烷和哌啶 |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| MY153985A (en) | 2007-12-18 | 2015-04-30 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
| CA2713184A1 (en) | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[2.2.1]heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| CA2739344A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| AU2009307915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010060472A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| JP2012509910A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| EP2370426A1 (en) | 2008-12-02 | 2011-10-05 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
| WO2010063662A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| JP2012522794A (ja) | 2009-04-03 | 2012-09-27 | メルク・シャープ・エンド・ドーム・コーポレイション | レニン阻害薬 |
| MX2011011127A (es) | 2009-04-24 | 2011-11-18 | Glaxo Group Ltd | 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina. |
| WO2010143116A1 (en) | 2009-06-09 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Fluorinated aminotriazole derivatives |
| HUE043962T2 (hu) | 2009-10-23 | 2019-09-30 | Janssen Pharmaceutica Nv | Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| WO2011090911A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| EA201370078A1 (ru) | 2010-09-24 | 2013-11-29 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| KR101995683B1 (ko) | 2012-06-04 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체 |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
-
2013
- 2013-10-09 SG SG11201502493XA patent/SG11201502493XA/en unknown
- 2013-10-09 US US14/434,997 patent/US9493446B2/en not_active Expired - Fee Related
- 2013-10-09 AR ARP130103661A patent/AR092955A1/es unknown
- 2013-10-09 AU AU2013328301A patent/AU2013328301A1/en not_active Abandoned
- 2013-10-09 EA EA201500399A patent/EA201500399A1/ru unknown
- 2013-10-09 EP EP13805561.1A patent/EP2906553B1/en active Active
- 2013-10-09 MX MX2015004638A patent/MX2015004638A/es unknown
- 2013-10-09 CN CN201380051391.3A patent/CN104703980B/zh not_active Expired - Fee Related
- 2013-10-09 WO PCT/IB2013/059233 patent/WO2014057435A1/en not_active Ceased
- 2013-10-09 KR KR1020157012089A patent/KR102151288B1/ko not_active Expired - Fee Related
- 2013-10-09 JP JP2015536264A patent/JP6244365B2/ja not_active Expired - Fee Related
- 2013-10-09 BR BR112015007516A patent/BR112015007516A2/pt not_active IP Right Cessation
- 2013-10-09 CA CA2885180A patent/CA2885180C/en active Active
- 2013-10-09 TW TW102136619A patent/TW201414727A/zh unknown
-
2015
- 2015-03-20 PH PH12015500627A patent/PH12015500627A1/en unknown
- 2015-03-31 IL IL238052A patent/IL238052A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2885180C (en) | 2021-03-02 |
| SG11201502493XA (en) | 2015-04-29 |
| US9493446B2 (en) | 2016-11-15 |
| AU2013328301A8 (en) | 2015-06-11 |
| JP6244365B2 (ja) | 2017-12-06 |
| EA201500399A1 (ru) | 2015-09-30 |
| MX2015004638A (es) | 2015-07-14 |
| CN104703980B (zh) | 2017-09-22 |
| KR102151288B1 (ko) | 2020-09-03 |
| JP2015533157A (ja) | 2015-11-19 |
| CN104703980A (zh) | 2015-06-10 |
| US20150252032A1 (en) | 2015-09-10 |
| CA2885180A1 (en) | 2014-04-17 |
| PH12015500627A1 (en) | 2015-05-11 |
| EP2906553B1 (en) | 2019-06-26 |
| WO2014057435A1 (en) | 2014-04-17 |
| BR112015007516A2 (pt) | 2017-07-04 |
| AU2013328301A1 (en) | 2015-05-28 |
| EP2906553A1 (en) | 2015-08-19 |
| IL238052A0 (en) | 2015-05-31 |
| KR20150064753A (ko) | 2015-06-11 |
| TW201414727A (zh) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR071323A1 (es) | Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii. | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| AR091257A1 (es) | Derivados de bencimidazol-prolina | |
| AR088235A1 (es) | Derivados de pirazoloquinolina | |
| AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| PE20140690A1 (es) | Benzoxazepinonas fusionadas como moduladoras de canales ionicos | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| AR077055A1 (es) | Derivados de benzimidazol como moduladores del canal trpm8 | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| EA201790661A2 (ru) | Ингибиторы вируса гепатита c | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| MX343264B (es) | Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos. | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |